Browsing Tag
Australia
722 posts
China faces coordinated diplomatic challenge over sweeping South China Sea claims
Fourteen nations and the EU reaffirmed the 2016 South China Sea ruling, intensifying legal pressure on Beijing as dangerous maritime clashes continue.
Victoria PLC (AIM: VCP) holds refinancing rally as £300m debt cut tests flooring recovery
Victoria’s refinancing could cut liabilities by £300m and finance costs by £34m. Investors now need proof that flooring recovery can follow.
Hays plc (LSE: HAS) shares jump as profit outlook improves despite weak hiring market
Hays plc rallied as profit guidance improved despite falling fees, raising the key question: is HAS seeing a turnaround or only a cost-led reprieve?
ASX uranium stocks rally as Australia-India deal revives nuclear fuel demand theme
ASX uranium stocks rallied after the Australia-India uranium deal. Read how Deep Yellow, Boss Energy and Paladin could be affected.
Seeing Machines (LSE: SEE) has the volume surge, but can it fix the balance sheet?
Seeing Machines has reached its automotive volume inflection. October refinancing will decide whether royalties can finally outrun cash risk.
WiseTech Global (ASX:WTC) rallies as new chair tests governance discount
WiseTech Global gained 10% on an independent chair, but Richard White remains influential. Can CargoWise growth outrun governance risk?
Echo IQ (ASX: EIQ) slips as A$110m raise tests AI valuation
Echo IQ has A$110m and blue-chip partners, but new shares are pressuring ASX. Can FDA clearance justify its A$1.1bn valuation?
China submarine missile test alarms Pacific as Australia, New Zealand and Japan object
China described the July 6 submarine-launched missile test as routine military training, but Pacific governments said limited notice and Beijing’s rapid military expansion created a fresh regional security concern.
Stakk shares fall as US$63m ParaScript acquisition tests dilution and AI trust strategy
Stakk’s ParaScript acquisition could transform its revenue, margins and United States footprint, but investors must weigh that growth against dilution, fixed payments and integration risk.
OncoSil Medical (ASX: OSL) rallies as FDA decision window opens
OncoSil is rallying into an FDA decision, but its trial was not designed to prove superiority. Can ASX turn clinical promise into sales?